Unchanged

Summary of findings {#CD008998-sec1-0001}
===================

Summary of findings for the main comparisonSummary of findings table**RDT diagnosis versus clinical diagnosis for managing patients with fever in malaria endemic settingsPatient or population:** People with fever **Settings:** Malaria endemic settings **Intervention:** Algorithms that include malaria RDTs **Control:** Algorithms based on clinical symptoms and signs only**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskClinical diagnosisRDT diagnosisPatients still unwell at day 4 to 755 per 100050 per 1000** (38 to 64)**RR 0.90** (0.69 to 1.17)6990 (5 trials)⊕⊕⊝⊝ **low**^1,2,3,4^**Patients prescribed antimalarials946 per 1000587 per 1000** (492 to 691)**RR 0.62** (0.52 to 0.73)17,287 (7 trials)⊕⊕⊕⊝ **moderate**^1,5,6,7^**Patients prescribed antibiotics**‐‐Not pooled13,573 (5 trials)⊕⊝⊝⊝ **very low**^1,8,9^**Patients with microscopically confirmed malaria not receiving antimalarials27 per 100033 per 1000** (17 to 62)**RR 1.21** (0.64 to 2.28)1280\
(1 trial)⊕⊕⊝⊝ **low**^10,11,12^The basis for the **assumed risk** is the median risk across control groups. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **HR:** Hazard ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Background {#CD008998-sec1-0002}
==========

Description of the condition {#CD008998-sec2-0001}
----------------------------

Malaria is a febrile illness, caused by infection with the *Plasmodium* parasite, and is spread from person to person by the bite of infected *Anopheles* mosquitoes. Five *Plasmodium* species infect humans, of which *Plasmodium falciparum* is the most common in Africa and responsible for most of the severe disease cases ([@CD008998-bbs2-0033]).

\'Uncomplicated\' malaria is the mild form of the disease which commonly presents as a fever. Light microscopy is the gold standard for confirming the diagnosis by detecting parasites in the symptomatic person\'s blood ([@CD008998-bbs2-0031]). However, the vast majority of malaria episodes and deaths occur in rural parts of Africa where diagnostic services are limited. Consequently diagnosis of malaria has often relied on clinical symptoms alone ([@CD008998-bbs2-0016]; [@CD008998-bbs2-0017]).

Description of the intervention {#CD008998-sec2-0002}
-------------------------------

Rapid diagnostic tests (RDTs) are individual test kits that can detect *Plasmodium‐*specific antigens in a drop of fresh blood using lateral flow immunochromatography ([@CD008998-bbs2-0030]; [@CD008998-bbs2-0034]). RDTs offer a feasible alternative to microscopy, particularly for rural first‐level health facilities, as they do not require a laboratory or special equipment, are simple to use with relatively little training, and provide a positive or negative result within 20 minutes ([@CD008998-bbs2-0034]).

Two RDT types are in common use; 1) HRP‐2; which detects a histidine‐rich protein produced by *P. falciparum,* and 2) pLDH; which detects the parasite lactate dehydrogenase (pLDH) enzymes produced by all species of *Plasmodium* that cause malaria in humans ([@CD008998-bbs2-0032]; [@CD008998-bbs2-0034]). A Cochrane Review of the diagnostic test accuracy of RDTs concluded that both tests were highly sensitive (having few false negative results) and highly specific (having few false positive results); HRP‐2: sensitivity = 95.0%, specificity = 95.2%; pLDH: sensitivity = 93.2%, specificity = 98.5% ([@CD008998-bbs2-0015]).

Interventions to introduce RDTs are usually multifactorial including: in‐service training and supervision of health workers, and dissemination of written guidelines or protocols, as well as introduction of the test itself. These supplementary interventions are necessary to assure adherence to diagnostic and treatment algorithms, and appropriate use of the RDT device under field conditions.

How the intervention might work {#CD008998-sec2-0003}
-------------------------------

The clinical symptoms associated with malaria are poor predictors of the disease. Reliance on clinical signs alone results in significant overuse of antimalarials, with between 32% and 93% of patients being falsely diagnosed with malaria, dependent on the local malaria endemicity ([@CD008998-bbs2-0021]; [@CD008998-bbs2-0025]; [@CD008998-bbs2-0036]). The introduction of RDTs to improve malaria diagnosis therefore has the potential to substantially reduce the over‐prescription of antimalarial drugs, by reducing the misclassification of fevers, especially in low prevalence areas ([@CD008998-bbs2-0022]; [@CD008998-bbs2-0036]; [@CD008998-bbs2-0037]). However, for patients that have malaria as the true cause of their fever, RDT introduction is unlikely to improve their health outcomes, as they would receive antimalarials even under an algorithm based on clinical symptoms (see [Figure 1](#CD008998-fig-0001){ref-type="fig"}). Instead, the potential health benefits of introducing RDTs are restricted to people whose fever is not due to malaria, for whom a negative RDT result should prompt the health worker to look for and treat the true cause of their fever. RDT introduction also has the potential for harm when false negative RDT results misclassify patients as not having malaria and consequently the appropriate antimalarial is not given or is delayed ([@CD008998-bbs2-0016]; [@CD008998-bbs2-0018]; [@CD008998-bbs2-0028]; [@CD008998-bbs2-0031]).Figure 1Logic framework for predicting the effect on health outcomes of using a HRP‐2 RDT with 95% sensitivity and 95.2% specificity ([@CD008998-bbs2-0015]).

Basic modelling, using the sensitivity and specificity of the HRP‐2 RDT gained from a Cochrane Review ([@CD008998-bbs2-0015]), predicts that areas of low malaria transmission have the greatest potential for health benefits as a result of introducing RDTs, and the lowest potential for harm from false negatives (see Figure 1). However, some suggest that in very low transmission settings where clinical malaria can occur at parasite densities lower than 100 parasites/µL of blood, RDTs may have lower sensitivity and lead to higher numbers of false negatives ([@CD008998-bbs2-0017]; [@CD008998-bbs2-0023]; [@CD008998-bbs2-0034]).

Widespread overuse of antimalarials is also thought to contribute to the development and spread of antimalarial resistance, and reductions in overuse through the use of RDTs could contribute to limiting this risk ([@CD008998-bbs2-0027]).

Why it is important to do this review {#CD008998-sec2-0004}
-------------------------------------

The World Health Organization now recommends that all suspected malaria cases receive a parasitological diagnosis prior to treatment ([@CD008998-bbs2-0031]), and RDTs are the most feasible way of achieving this in rural areas of Africa ([@CD008998-bbs2-0016]; [@CD008998-bbs2-0030]; [@CD008998-bbs2-0031]).

For policy makers seeking to introduce and improve malaria diagnosis in rural settings, this review aims to evaluate the effect of introducing RDTs into clinical algorithms on both the health outcomes for patients, and the unnecessary overuse of antimalarials. For health workers working in rural areas, this review also aims to evaluate the safety of RDT‐supported algorithms, and the potential for patients to be misdiagnosed as non‐malaria and sent home without appropriate treatment.

Objectives {#CD008998-sec1-0003}
==========

To evaluate whether introducing RDTs into algorithms for diagnosing and treating people with fever improves health outcomes, reduces antimalarial prescribing, and is safe compared to algorithms using clinical diagnosis.

Methods {#CD008998-sec1-0004}
=======

Criteria for considering studies for this review {#CD008998-sec2-0005}
------------------------------------------------

### Types of studies {#CD008998-sec3-0001}

Individual or cluster randomized controlled trials (RCTs).

### Types of participants {#CD008998-sec3-0002}

Patients with fever, or a reported history of fever, living in malaria endemic areas. We excluded trials conducted in non‐endemic areas (for example, fever in travellers in Europe).

### Types of interventions {#CD008998-sec3-0003}

#### Intervention {#CD008998-sec4-0001}

Diagnostic algorithms using RDTs to determine treatment for fever.

#### Control {#CD008998-sec4-0002}

Diagnostic algorithms based on clinical diagnosis to determine treatment for fever.

### Types of outcome measures {#CD008998-sec3-0004}

#### Clinical {#CD008998-sec4-0003}

Patients still unwell at day 4+ follow‐up.

#### Prescribing {#CD008998-sec4-0004}

Patients with fever prescribed antimalarials.Patients with fever prescribed antibiotics.

#### Safety {#CD008998-sec4-0005}

Microscopy‐positive patients not prescribed antimalarials.Microscopy‐negative patients prescribed antimalarials.

Search methods for identification of studies {#CD008998-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and ongoing).

### Electronic searches {#CD008998-sec3-0005}

We searched the following databases up to 10 January 2014 using the search terms described in [Appendix 1](#CD008998-sec2-0016){ref-type="app"}: Cochrane Infectious Disease Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in *The Cochrane Library*; MEDLINE; EMBASE; CINAHL; and LILACS.

In addition we searched the metaRegister of Controlled Trials (mRCT) and the WHO trials register using \"malaria\" AND \"rapid diagnostic test\*\" OR \"presumptive treatment\" as search terms.

### Searching other resources {#CD008998-sec3-0006}

#### Researchers and organizations {#CD008998-sec4-0006}

We contacted researchers in the field to identify additional trials that may have been eligible for inclusion.

#### Reference lists  {#CD008998-sec4-0007}

We checked the reference lists of all selected trials identified by the search strategy described above.

Data collection and analysis {#CD008998-sec2-0007}
----------------------------

### Selection of studies {#CD008998-sec3-0007}

John Odaga (JO) and Joseph A. Lokong (JAL) independently screened the abstracts in the search list for potentially relevant trials. We compared the list of potential articles independently identified by both authors. JO retrieved the full texts of the selected trials, which were made available to both authors. Both JO and JAL independently assessed each trial for inclusion, using an eligibility form based on the inclusion criteria. We included a trial if it satisfied all of the eligibility criteria. We resolved any disagreements by referring to the original articles or through discussions, or both, and where necessary by consulting Paul Garner (PG) and Sarah Donegan (SD).

### Data extraction and management {#CD008998-sec3-0008}

JO and PG independently extracted outcomes data from the included trials, guided by a standard data extraction form. We resolved any disagreements by referring to the original paper and through discussions. Where necessary, we sought clarification from trial authors by contacting them directly to provide relevant data missing from the included trials (for example, number of participants by age group, number of health centres excluded from analysis).

### Assessment of risk of bias in included studies {#CD008998-sec3-0009}

JO and PG independently assessed and judged the quality of the selected papers using the standard criteria ([@CD008998-bbs2-0020]). We assessed risk of bias against seven items: (1) how allocation sequence was generated (2) how allocation was concealed to participants, investigators and outcome assessors; (3) blinding of participants and investigators; (4) blinding of outcome assessors; (5) completeness of outcomes data (number analysed relative to number randomized) (6) selective reporting: whether all pre‐specified outcomes are reported; and (7) other sources of bias.

### Measures of treatment effect {#CD008998-sec3-0010}

For all the included outcomes we calculated a risk ratio (RR) and presented the results alongside the 95% confidence interval (CI).

### Unit of analysis issues {#CD008998-sec3-0011}

We performed analyses of all outcomes at individual levels using generic inverse variance method. Five of the included trials were cluster RCTs in which the unit of randomization were health facilities but analyses were performed at patient level.

Where trial authors had adjusted their results for the effect of clustering, we extracted the cluster adjusted RR and standard error and entered the natural log of these into [@CD008998-bbs2-0024] using the generic inverse variance method as recommended by [@CD008998-bbs2-0020].

Where trial authors had not adjusted their results for the effect of clustering, we extracted the simple summary data for all relevant outcomes and calculated crude RR & 95% CI using [@CD008998-bbs2-0024]. We adjusted for the effects of clustering using the approximate analysis method (as described in [@CD008998-bbs2-0020]). This involves inflating the standard error of the RR using an estimate of the design effect, and entering the natural logs of the adjusted RR and corresponding Standard Errors (SE) into [@CD008998-bbs2-0024] using the generic inverse variance method. For measures of antimalarial and antibiotic prescribing, we applied an external design effect of 3.8, as recommended by [@CD008998-bbs2-0026] for health facility surveys assessing antimalarial treatment in Benin. For other measures we used the design effect stated by the trial authors when calculating their sample size.

When trial authors had correctly adjusted their results for the effect of clustering, but presented their results as Odds Ratio (OR) rather than Risk Ratio (RR), we again extracted the simple summary data and conducted our own approximate adjustment for clustering as described above.

One trial was a cluster RCT with three clusters per group ([@CD008998-bbs2-0004], [@CD008998-bbs2-0003], [@CD008998-bbs2-0005]). However, we presented the data stratified by malaria endemicity where there was only one cluster per group. As a consequence, we could not make any adjustment for clustering. However, any clustering effect is likely to be very small, and unlikely to substantially affect the result or our interpretation.

### Assessment of heterogeneity {#CD008998-sec3-0012}

We assessed heterogeneity among trials by inspecting the forest plots for overlapping CIs. We also applied the Chi^2^ test for heterogeneity with a 10% level of statistical significance, and an I^2^ statistic value greater than 40% to denote moderate levels of heterogeneity ([@CD008998-bbs2-0020]).

### Data synthesis {#CD008998-sec3-0013}

We analysed the data using [@CD008998-bbs2-0024].

Where we had pooled data we used the generic inverse variance method which allows for meta‐analysis of both individually and cluster randomized trials. When we detected moderate levels of heterogeneity we combined trials using the random‐effects model which assumes the trials are estimating different, but related, intervention effects ([@CD008998-bbs2-0020]).

#### Quality of evidence {#CD008998-sec4-0008}

We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across trials has four levels: high, moderate, low, or very low. RCTs are initially categorized as high quality but can be downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias ([@CD008998-bbs2-0019]).

### Subgroup analysis and investigation of heterogeneity {#CD008998-sec3-0014}

Where we detected moderate heterogeneity, we performed subgroup analyses by stratifying results by the level of health worker adherence to the RDT result, the level of malaria endemicity, and the age group of the targeted population.

Results {#CD008998-sec1-0005}
=======

Description of studies {#CD008998-sec2-0008}
----------------------

### Results of the search {#CD008998-sec3-0015}

From the search strategy, we identified a total 273 abstracts of trial reports (after removal of duplicates) and ten records of ongoing trials (see [Figure 2](#CD008998-fig-0002){ref-type="fig"} for the study flow diagram). We did not deem any of the ongoing trials relevant to this review.Figure 2Study flow diagram.

### Included studies {#CD008998-sec3-0016}

We included seven RCTs that enrolled 17,505 participants; two individually RCTs ([@CD008998-bbs2-0001]; [@CD008998-bbs2-0002]), two published cluster‐RCTs ([@CD008998-bbs2-0006]; [@CD008998-bbs2-0007]), and three unpublished cluster‐RCTs ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0004]). For a summary of the trial characteristics see [Table 3](#CD008998-tbl-0003){ref-type="table"}, and for full details of individual trials see the \'[Characteristics of included studies](#CD008998-sec2-0020){ref-type="sec"}\' tables.Table 1Summary of characteristics of included studies**CharacteristicTrial ID**[@CD008998-bbs2-0001][@CD008998-bbs2-0002][@CD008998-bbs2-0007][@CD008998-bbs2-0006][@CD008998-bbs2-0005][@CD008998-bbs2-0003][@CD008998-bbs2-0004]**Setting**CountryGhanaBurkina FasoZambiaKenyaUgandaUgandaUgandaEndemicityNot indicatedSeasonalHigh and lowHigh and lowVery highHighMediumHealth facility, locationHealth centres or dispensaries; ruralDispensaries, rural & urbanCommunity postsHealth centres and hospitalsHealth centresHealth centresHealth centresUnit of randomizationIndividualsIndividualsClustersClustersClustersClustersClustersProportion of RDTs positive63%53%28%Not stated73%46%32%Proportion of reference slides positive38%Not statedNot stated4%54%37%29%**Participants**Number of health facilities3103130222Target population for malaria treatmentAllAll\< 5 years≥ 5 yearsAllAllAllNumber randomized3452216931252004419722131550Number analysed for antimalarial prescribing344221693047669^1^419722131550Loss to follow‐up0.3%0.0%2.5%‐0.0%0.0%0.0%**Outcomes reported**Clincal outcomesNoYesYesNoYesYesYesPrescribing of antimalarialsYesYesYesYesYesYesYesPrescribing of antibioticsYesYesNoNoYesYesYes[^3]

#### Setting {#CD008998-sec4-0009}

All seven RCTs were conducted in Africa, in rural areas of Ghana, Burkina Faso, Zambia, Kenya, and Uganda. All trials were undertaken in basic healthcare facilities without microscopes. The health workers responsible for diagnosing and treating patients with fever were community health workers in one trial ([@CD008998-bbs2-0007]), nurses In two trials ([@CD008998-bbs2-0001]; [@CD008998-bbs2-0002]), and a mix of clinical officers and nurses in four trials ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0004]; [@CD008998-bbs2-0006]).

Regarding malaria endemicity, [@CD008998-bbs2-0001] did not describe it, [@CD008998-bbs2-0002] described it as seasonal, and [@CD008998-bbs2-0006] and [@CD008998-bbs2-0007] described it as a mix of \'high and low\'. The three trials from Uganda were conducted in areas of \'very high\', \'high\' and \'medium\' endemicity respectively ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0004]). For subgroup analyses by endemicity we have used the proportion of RDTs testing positive as a surrogate marker for endemicity rather than these vague descriptors.

#### Interventions {#CD008998-sec4-0010}

The intervention consisted of training health workers to diagnose and treat patients with fever using clinical protocols incorporating RDTs. The duration of training was short (ranging from one half day in Kenya to five days in Zambia), and the level of ongoing supervision varied between trials (see [Table 4](#CD008998-tbl-0004){ref-type="table"}). Supportive supervision (observation of tasks with feedback) was provided monthly in Zambia, and once in Kenya (two months after training). In Uganda, no formal supervision was provided, and in Ghana and Burkina Faso the level of supervision was unclear.Table 2Description of the interventions**CharacteristicTrial ID**[@CD008998-bbs2-0001][@CD008998-bbs2-0002][@CD008998-bbs2-0007][@CD008998-bbs2-0006][@CD008998-bbs2-0005][@CD008998-bbs2-0003][@CD008998-bbs2-0004]**Training**Who was trained to follow the RDT algorithm?Nurses and nursing assistantsNursesCommunity health workersNurses, clinical officers and doctorsClinical officers and nursesClinical officers and nursesClinical officers and nursesWho conducted the training?Nurses, after a TOT courseNot describedExperienced IMCI trainersClinical officers and nurses, after a two‐ week TOT courseExperienced national trainersExperienced national trainersExperienced national trainersHow long was the training? (days)235Half‐day333Was a written guideline provided?UnclearUnclearUnclearYesYesYesYesWhat supervision was conducted?UnclearUnclearReview of records and feedback each monthObservation and feedback once after two monthsOne day of supportive supervision two weeks after the trainingOne day of supportive supervision two weeks after the trainingOne day of supportive supervision two weeks after the trainingWere staff incentives provided?NoNoBicyclesNoNoNoNoWho conducted the RDT tests?Research staffResearch staffPrescribersPrescribersPrescribersPrescribersPrescribersWhich RDT‐typeOptiMAL‐IT (pLDH)Paracheck (HRP‐2)ICT malaria Pf (HRP‐2)Paracheck (HRP‐2)Paracheck (HRP‐2)Paracheck (HRP‐2)Paracheck (HRP‐2)Were the RDTs provided free?YesYesYesYesYesYesYesWere the antimalarials provided free?YesYesYesYesYesYesYesWere the antibiotics provided free?YesYesYesYesYesYesYes**Algorithm**Test all cases of fever with RDTsYesYesYesYesYesYesYesPrescribe only if RDT is positiveYesYesYesYesYesYesYesDo not prescribe if RDT is negativeYesYesYesYesYesYesYesTreatment of RDT negative casesNot describedLook for other causes and treat as per STGAmoxicillin if signs of pneumonia; else referNot describedLook for other causes and treat as per STGLook for other causes and treat as per STGLook for other causes and treat as per STGGuideline on prescribing antibioticsNot mentionedNot mentionedNot mentionedIf pneumonia is suspectedNot mentionedNot mentionedNot mentioned

In two trials, members of the research team conducted the RDT tests and then sent the results to the health workers for interpretation and treatment ([@CD008998-bbs2-0001]; [@CD008998-bbs2-0002]). The authors state that this approach aimed to optimise the quality of RDT results and minimise time pressure on the health workers. In the Zambian, Kenyan, and Ugandan trials, the clinical officers, nurses or community health workers carried out the test themselves.

Only four trials reported to have provided written guidelines to the intervention health facilities following training ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0004]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0006]), and only five trials included in their training a clear message about the need for health workers to look for alternative causes of fever in patients with negative RDTs ([@CD008998-bbs2-0002]; [@CD008998-bbs2-0005]; [@CD008998-bbs2-0004]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0006]).

RDTs, antimalarials, and antibiotics were provided to patients free of charge in all trials.

#### Adherence to algorithm {#CD008998-sec4-0011}

Only the three trials from Uganda provide data on the extent to which RDTs were conducted in the intervention arm. In these trials, at least 97% of all fever cases were tested by RDTs to confirm the presence of malaria prior to treatment ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0004]). Six trials provide data on the proportion of RDT‐positive patients for whom antimalarials were prescribed (see [Table 5](#CD008998-tbl-0005){ref-type="table"}). Health workers prescribed antimalarials to 98% to 100% of cases with positive RDTs, and to up to 81% of patients with negative RDTs. Where this is likely to have affected the outcome we conducted subgroup analyses by level of health worker adherence.Table 3Assessment of endemicity and health worker adherence**Trial IDAge groupProportion of RDTs positive (%)Proportion of reference slide positive (%)Endemicity classification^1^Proportion of patients prescribed antimalarials (%)Health worker adherence classification^2^RDT armClinical arm**[@CD008998-bbs2-0005]All7354Very high7295High[@CD008998-bbs2-0002]All55‐High8987Very low[@CD008998-bbs2-0003]All4637High4598High[@CD008998-bbs2-0001]All4138High7093Low[@CD008998-bbs2-0004]All3229Moderate3298High[@CD008998-bbs2-0007]\< 528‐Moderate2899High[@CD008998-bbs2-0006]\> 5‐4Low4154Very low^3^[^4]

#### Participants {#CD008998-sec4-0012}

One trial targeted children under the age of five years ([@CD008998-bbs2-0007]), one trial targeted older children ([@CD008998-bbs2-0006]), and five trials targeted all age groups. All trials recruited participants with fever or history of fever except the three unpublished trials which recruited participants with any complaint. However, for these unpublished trials we restricted our analysis to only the subgroup of participants which presented with fever.

### Excluded studies {#CD008998-sec3-0017}

We excluded seven trials and listed the reasons in the [Characteristics of excluded studies](#CD008998-sec2-0021){ref-type="sec"} table.

Risk of bias in included studies {#CD008998-sec2-0009}
--------------------------------

We have presented a summary of the risk of bias assessment in [Figure 3](#CD008998-fig-0003){ref-type="fig"}.Figure 3Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial. Green = low risk of bias, red = high risk of bias, yellow = unclear risk of bias.

### Allocation {#CD008998-sec3-0018}

Only one trial adequately described both sequence generation and allocation concealment to be considered at low risk of selection bias ([@CD008998-bbs2-0001]). The remaining six trials were at unclear risk due to inadequate descriptions of allocation concealment.

### Blinding {#CD008998-sec3-0019}

Blinding of participants and health workers to the use of RDTs was not be possible. However, blinding of the outcome assessment was possible in all trials but was not described in any of them.

### Incomplete outcome data {#CD008998-sec3-0020}

Attrition bias was at low risk of bias (≤ 3%) in six trials, and in one trial the attrition rate was high (30%) and unequal in the two arms ([@CD008998-bbs2-0006]).

### Selective reporting {#CD008998-sec3-0021}

All trials reported outcomes that were pre‐specified in the methods sections of their protocols and reports. The risk of selective reporting was low.

### Other potential sources of bias {#CD008998-sec3-0022}

Three trials ([@CD008998-bbs2-0001]; [@CD008998-bbs2-0006]; [@CD008998-bbs2-0007]) acknowledged baseline imbalance in the number or quality of the health workers enrolled into the trial, which were adjusted for using different methods.

Effects of interventions {#CD008998-sec2-0010}
------------------------

See: [Table 1](#CD008998-tbl-0001){ref-type="table"}

See [Table 1](#CD008998-tbl-0001){ref-type="table"} for a summary of the results and GRADE appraisal of the quality of evidence.

### Clinical outcomes {#CD008998-sec3-0023}

#### Patients still unwell at day 4+ follow‐up {#CD008998-sec4-0013}

Five trials from settings with very high, high, and moderate malaria endemicity, reported the proportion of patients who were still unwell four to seven days after treatment, and found no significant differences between clinical and RDT‐supported diagnosis (RR 0.90, 95% CI 0.69 to 1.17, 6990 participants, five trials, [Analysis 1.1](#CD008998-fig-00101){ref-type="fig"}, [Figure 4](#CD008998-fig-0004){ref-type="fig"}). The absolute numbers of participants remaining unwell ranged from 2.8 to 9.3% in those diagnosed with an RDT, and from 4.1 to 10.8% in those diagnosed clinically (see [Appendix 2](#CD008998-sec2-0017){ref-type="app"}).Figure 4Forest plot of comparison: 1 RDT‐supported diagnosis versus Clinical diagnosis, outcome: 1.1 Patients still unwell at follow‐up at day 4+.

Statistical heterogeneity was low (I^2^ = 0%). However, in one trial health worker compliance with the RDT‐supported diagnosis was very low, with a high prescription of antimalarials in both groups regardless of the RDT result ([@CD008998-bbs2-0002]). This trial found no difference between the intervention arms in the proportion of cases who were still unwell at follow‐up (2095 participants, one trial, [Analysis 1.2](#CD008998-fig-00102){ref-type="fig"}). In the remaining trials with improved health worker compliance, there is a trend towards a health benefit with using RDTs, although the CI is wide and includes the possibility of no difference between groups (4895 participants, four trials, [Analysis 1.2](#CD008998-fig-00102){ref-type="fig"}).

### Prescribing outcomes {#CD008998-sec3-0024}

#### Patients with fever prescribed antimalarials {#CD008998-sec4-0014}

Although fewer patients in the group with RDT‐supported diagnosis were prescribed antimalarials there is substantial heterogeneity between trials, with no impact on prescribing in one trial and moderate or large effects in the others (17,287 participants, seven trials, I² = 98%, [Analysis 1.3](#CD008998-fig-00103){ref-type="fig"}). This variation seems most related to health worker adherence to the RDT‐supported protocol ([Figure 5](#CD008998-fig-0005){ref-type="fig"}). In the trial from Burkina Faso health workers prescribed antimalarials to 81% of patients with negative RDT results, and consequently no difference in antimalarial prescribing was detected (RR 1.02, 95% CI 0.99 to 1.06, 2169 participants, one trial, [Analysis 1.4](#CD008998-fig-00104){ref-type="fig"}). In the four trials in which health worker adherence was high, the reduction in prescribing of antimalarials was large ([Analysis 1.4](#CD008998-fig-00104){ref-type="fig"}, [Figure 5](#CD008998-fig-0005){ref-type="fig"}).Figure 5Forest plot of comparison: 1 RDT‐supported diagnosis versus Clinical diagnosis, outcome: 1.4 Patients with fever prescribed antimalarials; subgrouped by health worker adherence to the RDT result.

Within the subgroup of trials with high health worker adherence, the relative malaria endemicity also seems to influence the size of the reduction in antimalarial prescriptions. The biggest reductions were seen where less than 30% of people presenting with fever tested positive by RDT, and smaller reductions were seen where RDT positivity was greater than 40%, or greater than 70% (11,007 participants, four trials, [Analysis 1.5](#CD008998-fig-00105){ref-type="fig"}).

We also conducted a subgroup analysis by age of participants, and the reduction in antimalarial use appears largest in participants over the age of five ([Analysis 1.6](#CD008998-fig-00106){ref-type="fig"}). We were unable to assess whether this difference was due to reduced health worker adherence when treating children aged less than five as the data were unavailable.

#### Patients with fever prescribed antibiotics {#CD008998-sec4-0015}

Five trials reported the proportion of patients prescribed antibiotics with very variable results (13,573 participants, five trials, [Analysis 1.7](#CD008998-fig-00107){ref-type="fig"}).

In Burkina Faso, where compliance with the RDT result was very low and no difference was seen in antimalarial prescribing behaviour, there was also no difference in antibiotic prescribing ([@CD008998-bbs2-0002], [Analysis 1.7](#CD008998-fig-00107){ref-type="fig"}). In the two trials with the largest relative reduction in antimalarial prescribing, there was no significant difference in antibiotic prescribing between groups (([@CD008998-bbs2-0004]; [@CD008998-bbs2-0003], [Analysis 1.7](#CD008998-fig-00107){ref-type="fig"}). In these trials, the RDT protocol did not recommend antibiotics for all RDT negative patients but instead advised the health worker to look for other causes of fever and treat appropriately.

In the Uganda setting with very high endemicity, where over 70% of RDTs were positive, and antimalarial prescribing was reduced by a quarter the RDT protocol also reduced antibiotic prescribing ([@CD008998-bbs2-0005], [Analysis 1.7](#CD008998-fig-00107){ref-type="fig"}). Conversely, in Ghana where 63% of RDTs were positive and antimalarial prescribing was also reduced by a quarter, antibiotic prescribing increased in the RDT group ([@CD008998-bbs2-0001], [Analysis 1.7](#CD008998-fig-00107){ref-type="fig"}).

### Safety outcomes {#CD008998-sec3-0025}

#### Microscopy positive patients not prescribed antimalarials {#CD008998-sec4-0016}

Only one trial conducted microscopy on all participants in both intervention arms allowing identification of malaria cases \'missed\' by the RDT‐supported protocol, or \'false negatives\' ([@CD008998-bbs2-0001]). This trial was conducted in Ghana where 63% of RDTs were positive for malaria. The proportion of reference slide positive patients not prescribed antimalarials was higher with the use of RDTs but this did not reach statistical significance (1280 participants, one trial, [Analysis 1.8](#CD008998-fig-00108){ref-type="fig"}).

In addition, the three trials from Uganda conducted microscopy on just the participants in the arms using RDT‐supported diagnosis. The proportion of microscopy positive patients not given antimalarials due to a negative RDT result was 2.0% in the very high endemic setting (95% CI 1.2% to 2.8%, 1187 participants), 4.5% in the high endemic setting (95% CI 2.3% to 6.6%, 357 participants), and 17.2% in the area of medium endemicity (95% CI 11.6% to 22.8%, 174 participant). [Table 6](#CD008998-tbl-0006){ref-type="table"} examines how these figures translate into negative and positive predictive values in the different settings. In the area of medium endemicity, the accuracy of RDTs performed by health workers was not as high as in settings of high and very high endemicity with a sensitivity of 82.8%, and specificity of 72.2%. Consequently, the negative predictive value of a negative RDT in this setting is 0.93, which means that for every 100 patients with a negative RDT result, seven patients will have malaria parasites demonstrated by microscopy (false negatives).Table 4Negative and positive predictive values of RDTs in trials by Hopkins et al**Trial IDProportion of reference slides positiveNumber of patients^1^Sensitivity^6^ (95% CI)Specificity^7^ (95% CI)NPV^8^PPV^9^TP^2^FP^3^TN^4^FN^5^**[@CD008998-bbs2-0005]55%1165 (51.1%)454 (19.9%)633 (27.8%)26 (1.1%)97.8%59.4%96.2%72.0%[@CD008998-bbs2-0003]37%347 (33.7%)100 (9.7%)567 (55.0%)17 (1.7%)95.3%85.0%97.1%77.6%[@CD008998-bbs2-0004]29%145 (24.6%)45 (7.5%)378 (63.2%)30 (5.0%)82.9%89.4%92.7%76.3%[^5]

#### Microscopy negative patients prescribed antimalarials {#CD008998-sec4-0017}

The same trial from Ghana also allows identification of \'false positives\'; the number of patients without malaria on microscopy who tested positive by RDT and received antimalarials ([@CD008998-bbs2-0001]). In this trial RDT‐supported diagnosis significantly reduced the over treatment of malaria (RR 0.60, 95% CI 0.57 to 0.64, 2162 participants, one trial, [Analysis 1.9](#CD008998-fig-00109){ref-type="fig"}), but 53.9% of people with negative microscopy still received antimalarials.

In the three trials from Uganda, which conducted microscopy on just the participants in the arms using RDT‐supported diagnosis, the proportions of slide negative participants who were prescribed antimalarials because they tested positive on RDT (false positives) was 34.4% in the medium transmission setting (95% CI 29.9% to 39.0%, 418 participants), 15.2% in the high transmission setting (95% CI 12.4% to 18.1%, 617 participants), and 43.9% in the very high transmission setting (95% CI 40.8 to 46.9%, 1028 participants).

Discussion {#CD008998-sec1-0006}
==========

Summary of main results {#CD008998-sec2-0011}
-----------------------

Seven trials, enrolling 17,505 participants, are included in this review; two individually RCTs and five cluster RCTs.

In most trials the health workers diagnosing and treating malaria were nurses or clinical officers who had undergone less than one week of training in RDT supported diagnosis. Health worker adherence to the RDT result was highly variable, with the percentage of participants with a negative RDT result who received antimalarials ranging from 0% to 81%.

In these trials, RDT‐supported diagnosis had little or no effect on the number of participants remaining unwell at four to seven days after treatment (*low quality evidence*).

However, using RDTs reduced the prescription of antimalarials by up to three‐quarters (*moderate quality evidence*), and as would be expected reductions in prescribing of antimalarials were highest where health workers adherence to the RDT result was high, and where the true prevalence of malaria was lower.

Using RDTs to support diagnosis did not have a consistent effect on the prescription of antibiotics with some trials showing an increase in antibiotic prescription and some showing a decrease (*very low quality evidence*).

In a single trial from a setting with moderate endemicity, which reported microscopy results for all enrolled patients, RDT supported diagnosis did not result in a statistically significant excess of patients with microscopically confirmed malaria who did not receive antimalarials (*low quality evidence)*.

Overall completeness and applicability of evidence {#CD008998-sec2-0012}
--------------------------------------------------

The included trials were all conducted in first‐level health facilities in rural areas of Africa, where the majority of malaria cases occur, and where RDTs offer the only feasible alternative to presumptive treatment of malaria based on clinical symptoms alone. These trials are from settings with a range of levels of malaria endemicity, and the findings could reasonably be applied to other similar African settings.

The main concern of health workers regarding the use of RDTs is the risk of missing malaria cases and sending children home without antimalarials when the result of the RDT is a false negative ([@CD008998-bbs2-0016]; [@CD008998-bbs2-0017]; [@CD008998-bbs2-0023]; [@CD008998-bbs2-0034]). Reassuringly, this review found no difference in patient health outcomes when RDTs are introduced, and the trend is in the direction of benefit. However, only one trial adequately evaluated the risk of false negative results by applying the gold standard light microscopy to all fever patients in both treatment arms ([@CD008998-bbs2-0001]), and although the result did not reach statistical significance the trend was towards higher numbers of missed cases when RDTs were used.

The additional trial from Uganda, which reported decreased RDT sensitivity in the setting with lowest endemicity adds to this concern. In this setting, of 404 patients with negative RDTs, 30 (7%) had malaria parasites following microscopy analysis. This risk may be considered too high by some patients and health workers unless adequate measures are taken to ensure the safety of these patients, such as routine follow‐up at 24 or 48 hours and repeat testing if they remain unwell. These data also raise concerns about the performance of RDTs in real‐life clinical scenarios. The cause of the low sensitivity is not clear, and may be user‐dependent, but reassuringly this trial appears to be an outlier when seen in the context of all the observational data on RDT sensitivity and specificity (see [Figure 6](#CD008998-fig-0006){ref-type="fig"}). Of the 71 trials of HRP‐2 RDTs included in the Cochrane diagnostic test accuracy review, 51 were conducted in areas of lower endemicity with a pooled sensitivity of 95.1% (95% CI 93.1 to 96.6) and specificity of 95.9% (95% CI 94.1 to 97.2) ([@CD008998-bbs2-0015]).Figure 6Sensitivity and specificity of 71 trials of HRP‐2 RDTs included in the Cochrane Review of RDTS for diagnosing *P. falciparum* malaria ([@CD008998-bbs2-0015]). The data from [@CD008998-bbs2-0004] is represented with a blue circle at sensitivity 0.829 and specificity 0.894.

The five trials included in this review show no clear trend in prescribing of antibiotics which may indicate inconsistency in protocols for managing RDT negative results. This is surprising given that those with negative RDTs are the only people who will potentially benefit from the introduction of RDTs and also those who will potentially be harmed. Future research, and future programmes, should concentrate on improving health worker guidance and patient health outcomes in this group.

Quality of the evidence {#CD008998-sec2-0013}
-----------------------

We assessed the quality of the evidence using the GRADE approach and presented the basis for the judgements in [Table 1](#CD008998-tbl-0001){ref-type="table"}.

The evidence that introducing RDTs has little or no effect on health outcomes is of low quality, meaning we can only have limited confidence in this result. Although there were minor concerns about risk of bias (with none of the trials adequately minimising the risk of selection bias), and inconsistency (with one trial with very poor health worker adherence finding no evidence of an effect), the main reasons for downgrading the evidence were \'indirectness\' and \'imprecision\'. The evidence is indirect because health benefits of introducing RDTs will only be seen with adequate treatment of the fevers not caused by malaria. In these trials, the management protocol for patients with negative RDTs was unclear, and the mixed effects on antibiotic prescribing may suggest that the management of these patients was erratic. Once we excluded the trial with poor health worker adherence ([@CD008998-bbs2-0002]), there was a consistent trend towards benefit with the use of RDTs although this did not reach statistical significance. Larger trials may be necessary to show statistically significant benefits if they exist.

The evidence that introducing RDTs can substantially reduce the overuse of antimalarials is of moderate quality, meaning we can have reasonable confidence in this result. We downgraded the evidence due to concerns about inconsistency between trials, with large effects in some and complete absence of effects in others. This inconsistency is best explained by the variation in adherence of health workers to negative RDT results. Consequently, to see the reductions in antimalarial use predicted by the known malaria prevalence in any setting, healthcare managers will need to ensure adequate training, support, and supervision for health workers in the use of RDTs, and in the management of patients who test negative.

The evidence that using RDTs does not increase the proportion of patients with malaria who are sent home without antimalarials is of low quality, meaning we can have only limited confidence in this result. This result is from a single trial setting, and was downgraded for serious indirectness as the result is poorly applicable to elsewhere. The 95% CI is also wide and includes the possibility of clinically important harms with RDTs and was downgraded for serious imprecision.

Potential biases in the review process {#CD008998-sec2-0014}
--------------------------------------

We have reported the RDT sensitivity and specificity of a single arm from a trial at three sites in Uganda because this data was available to us ([@CD008998-bbs2-0005]; [@CD008998-bbs2-0003]; [@CD008998-bbs2-0004]). However, this information is observational, and in this review we did not search for all trials that would present this information. These data therefore should only be considered in the context of the wider body of evidence included in the Cochrane Review by [@CD008998-bbs2-0015].

Agreements and disagreements with other studies or reviews {#CD008998-sec2-0015}
----------------------------------------------------------

The review results are supported by findings from several quasi‐experimental and observational studies excluded from this review.

For health outcomes, two weekly cross‐over trials from Tanzania found no change in mortality with the introduction of RDTs. However, in one of these studies RDTs were associated with a decrease in the proportion of patients remaining unwell two weeks after treatment ([@CD008998-bbs2-0012]), and in the other RDTs were associated with an increase in the proportion still unwell after seven days of treatment ([@CD008998-bbs2-0013]).

For prescribing outcomes, several non‐RCTs have found reductions in antimalarial prescribing following the introduction of RDTs, especially in low transmission areas ([@CD008998-bbs2-0035]; [@CD008998-bbs2-0009]; [@CD008998-bbs2-0011]; [@CD008998-bbs2-0012]; [@CD008998-bbs2-0014]). Routine data from a large scale implementation project in Senegal found similar results over a three year period providing some evidence that RDTs reduce prescribing of antimalarials in routine practice as well as under experimental conditions ([@CD008998-bbs2-0029]).

Authors\' conclusions {#CD008998-sec1-0007}
=====================

Algorithms incorporating RDTs can substantially reduce antimalarial prescribing if health workers adhere to the test results. The introduction of RDTs has not been shown to improve health outcomes for patients but adherence to the test result does not seem to result in worse clinical outcomes than presumptive treatment. Concentrating on improving the care of RDT negative patients could improve health outcomes in febrile children.These trials were performed as these new RDT technologies were being rolled out, so observational studies and audits of guideline implementation will help monitor adherence over time.Decision making around the use of RDTs could be further informed by:Continued evaluation of RDT sensitivity under operational conditions in settings with moderate or low endemicity,Better quantification of the risk of patient harm to those with false negative RDT results,Better quantification of the causes of non‐malaria fevers in these settings,Design and evaluation of interventions aimed at improving the care of RDT negative patients such as improved protocols which include routine follow‐up or repeat RDT testing at 24 to 48 hours if patients remain unwell.

The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development (DFID) for the benefit of low‐ and middle‐income countries.

We thank Katherine Abba for permission to reproduce Figure 7 from [@CD008998-bbs2-0015].

The data synthesised in this review is from John Odaga\'s PhD thesis, which was funded by the Commonwealth Scholarship Commision (UK).

**Search setSearch terms**1Malaria2Fever3Febrile illness41 or 2 or 35Rapid diagnostic test6RDT7Presumptive treatment8Syndromic approach9Treatment practice10Management11Prescription behaviour12Definite diagnosis135‐12/or14randomized controlled trial15random allocation16double blind method17single blind method18randomly19Clinical trials2014‐19/or214 and 13 and 20\* \* Search terms 14‐19 will not be applied to CENTRAL

**TrialRDT algorithmClinical algorithmEvents (%)TotalEvents (%)Total1.0 Patients1.1**\
**Patients prescribed antimalarials**[@CD008998-bbs2-0007]\*27.596399.12084[@CD008998-bbs2-0004]31.760299.3948[@CD008998-bbs2-0003]43.9107398.01140[@CD008998-bbs2-0005]70.8228894.61909[@CD008998-bbs2-0006]40.935954.2310[@CD008998-bbs2-0001]70.0171992.71723[@CD008998-bbs2-0002]89.3105887.21111**1.2**\
**Microscopy positive patients receiving antimalarials**[@CD008998-bbs2-0001]96.864797.3633**1.2**\
**Microscopy positive patients missing antimalarials**[@CD008998-bbs2-0001]3.26472.7633**1.3**\
**Microscopy negative patients receiving antimalarials**[@CD008998-bbs2-0001]53.9107290.11090**1.4**\
**Number prescribed antibiotics**[@CD008998-bbs2-0002]52.9105854.81111[@CD008998-bbs2-0004]52.060247.8948[@CD008998-bbs2-0003]51.9107357.11140[@CD008998-bbs2-0005]42.5228858.91909[@CD008998-bbs2-0001]26.6171922.31723**1.5**\
**Patients still unwell at follow‐up at day 4, or after**[@CD008998-bbs2-0007]9.3101710.02108[@CD008998-bbs2-0004]2.81414.8187[@CD008998-bbs2-0003]3.72164.1267[@CD008998-bbs2-0005]9.357110.8388[@CD008998-bbs2-0002]5.610245.51071**2.0 Subgroups2.1**\
**Fever patients receiving antimalarials2.1.1**\
\< 5 years[@CD008998-bbs2-0007]\*27.596399.12084[@CD008998-bbs2-0001]80.051992.5550[@CD008998-bbs2-0004]46.916099.1214[@CD008998-bbs2-0003]55.336798.3354[@CD008998-bbs2-0005]83.3136093.4934**2.1.2**\
≥ 5 years[@CD008998-bbs2-0001]65.8120092.81173[@CD008998-bbs2-0006]40.935954.2310[@CD008998-bbs2-0004]26.244299.3734[@CD008998-bbs2-0003]38.070697.8786[@CD008998-bbs2-0005]52.492895.8975\*RRs calculated from these summary statistics may be different from those in the analysis. In the analysis, the review authors extracted RRs which had been adjusted for clustering and baseline imbalance.

Comparison 1RDT‐supported diagnosis versus Clinical diagnosisOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Patients still unwell at follow‐up at day 4+](#CD008998-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 1 Patients still unwell at follow‐up at day 4+.56990Risk Ratio (Random, 95% CI)0.90 \[0.69, 1.17\][2 Patients still unwell at follow‐up at day 4+; subgrouped by health worker adherence to the RDT result](#CD008998-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 2 Patients still unwell at follow‐up at day 4+; subgrouped by health worker adherence to the RDT result.56990Risk Ratio (Random, 95% CI)0.90 \[0.69, 1.17\]2.1 Very low health worker adherence12095Risk Ratio (Random, 95% CI)1.01 \[0.73, 1.41\]2.2 High health worker adherence44895Risk Ratio (Random, 95% CI)0.74 \[0.48, 1.14\][3 Patients with fever prescribed antimalarials](#CD008998-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 3 Patients with fever prescribed antimalarials.717287Risk Ratio (Random, 95% CI)0.62 \[0.52, 0.73\][4 Patients with fever prescribed antimalarials; subgrouped by health worker adherence to the RDT result](#CD008998-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 4 Patients with fever prescribed antimalarials; subgrouped by health worker adherence to the RDT result.7Risk Ratio (Random, 95% CI)Subtotals only4.1 High health worker adherence411007Risk Ratio (Random, 95% CI)0.44 \[0.29, 0.67\]4.2 Low health worker adherence13442Risk Ratio (Random, 95% CI)0.76 \[0.74, 0.79\]4.3 Very low health worker adherence22838Risk Ratio (Random, 95% CI)0.90 \[0.68, 1.20\][5 Patients with fever prescribed antimalarials; trials with high health worker adherence subgrouped by malaria prevalence (RDT positivity)](#CD008998-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 5 Patients with fever prescribed antimalarials; trials with high health worker adherence subgrouped by malaria prevalence (RDT positivity).4Risk Ratio (Random, 95% CI)Subtotals only5.1 Very high endemicity (\> 70% of RDTs positive)14197Risk Ratio (Random, 95% CI)0.75 \[0.73, 0.77\]5.2 High endemicity (40% to 70% of RDTs positive)12213Risk Ratio (Random, 95% CI)0.45 \[0.40, 0.51\]5.3 Moderate endemicity (\< 40% RDTs positive)24597Risk Ratio (Random, 95% CI)0.32 \[0.19, 0.53\][6 Patients with fever prescribed antimalarials; subgrouped by age](#CD008998-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 6 Patients with fever prescribed antimalarials; subgrouped by age.6Risk Ratio (Random, 95% CI)Subtotals only6.1 \< 5yrs57505Risk Ratio (Random, 95% CI)0.61 \[0.27, 1.37\]6.2 ≥ 5 yrs57613Risk Ratio (Random, 95% CI)0.51 \[0.38, 0.67\][7 Patients with fever prescribed antibiotics](#CD008998-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 7 Patients with fever prescribed antibiotics.513573Risk Ratio (Random, 95% CI)0.99 \[0.85, 1.16\][8 Microscopy‐positive patients not prescribed antimalarials](#CD008998-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 8 Microscopy‐positive patients not prescribed antimalarials.11280Risk Ratio (Fixed, 95% CI)1.21 \[0.64, 2.28\][9 Microscopy‐negative patients prescribed antimalarials](#CD008998-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 RDT‐supported diagnosis versus Clinical diagnosis, Outcome 9 Microscopy‐negative patients prescribed antimalarials.12162Risk Ratio (Random, 95% CI)0.60 \[0.57, 0.64\]

**DateEventDescription**8 May 2014AmendedThere were minor errors in the values for assumed and corresponding risk in [Table 1](#CD008998-tbl-0001){ref-type="table"} which we have corrected. In addition, we corrected references provided in some of the footnotes to forest plots from Hopkins 2010 to Hopkins 2008.

We included PG, DS and HH as authors.

Regarding outcomes:

We paraphrased measure of clinical outcomes to \"patients still unwell at day 4+ of follow‐up\" and considered it as a primary outcome. In the protocol we considered \"persistence of fever at day 4+, based on self‐report‐‐not confirmed by means of a thermometer\" as a secondary outcome.We included \"Parasitaemia on day 4+\" as a primary outcome in the protocol. We deleted this in the review because the trials included are pragmatic in nature and did not assess parasitaemia.\"Microscopy positive patients not receiving antimalarials\" was included as a secondary outcome because it is an issue of concern to decision‐makers.We included \"Microscopy negative patients prescribed antimalarials\" as a secondary outcome measure because it is a measure of antimalarial wastage, which is one of the primary reasons for introducing RDT‐based policies.

Characteristics of included studies \[ordered by study ID\] {#CD008998-sec2-0020}
===========================================================

[@CD008998-bbs2-0001]MethodsTrial design: individually RCT\
Patients evaluated on day 28\
Reference slides taken on all patientsParticipantsChildren and adults with suspected malaria\
Exclusion: pregnancy, illness requiring admission, non‐compliance with allocated test or treatment, not living locally\
Number of participants randomized: 3452\
Number analysed for primary outcome (prescribing of antimalarials): 3442 (0.3% loss to follow‐up)InterventionsRDT plus treatment versus clinical diagnosis plus treatment.\
(A second component examining RDT versus microscopy did not meet our entry criteria).\
Health workers in both groups received training and held guidelines\
RDT performed by research team\
Health workers complied with guidelines partially: 49.5% of participants with negative RDT results received antimalarialsOutcomesPrimary:\
Patients treated with antimalarials who did not have malaria based on reference slide.\
Secondary:\
Patients not receiving antimalarial treatment who were malaria reference slide positive.Patients prescribed antibioticsPatients with positive reference slide not prescribed antimalarialsPatients correctly treated (patients that were reference slide positive and treated with antimalarials plus patients that were reference slide negative and not prescribed antimalarial treatment)NotesCountry: Ghana\
RDT: OptiMAL‐IT\
Setting: three health centres, of all referral levels\
Transmission: not indicated\
Dates: July 2007 to December 2008\
Funding: Gates Malaria Partnership***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated blocks of 10.Allocation concealment (selection bias)Low riskNumbers placed in sealed opaque envelopes.Blinding of participants and personnel (performance bias) All outcomesHigh riskTrial participants and staff were aware of allocated tests, the results, and prescriptions.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnostic outcomes and the medications prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was low and comparable in both settings (≤ 3%).Selective reporting (reporting bias)Low riskReported on all ‐ outcomes specified in prospective trial register.Other biasLow riskNo other sources of bias identified.[@CD008998-bbs2-0002]MethodsTrial design: individually RCT\
lasting two months, one month in rainy season, one month in dry seasonParticipantsNumber of participants randomized: 2169 (1058 in RDT arm, 1111 in presumptive treatment arm)\
Number analysed for primary outcomes: (a) prescribing of antimalarials analysis 2169 (0% loss); (b) clinical outcomes: 2095 (3.4% loss)\
Inclusion: age ≥ 6 years; axillary temperature ≥ 37.5°C\
Exclusion: severe malariaInterventionsIntervention: RDT‐based policy for fever\
Control: Presumptive treatment\
Both groups received training and held guidelines\
RDT performed by research team\
Health workers did not comply with guidelines most of the time: 81% of participants with negative RDT results received antimalarialsOutcomesPrimary: patients with fever on day 4\
Secondary:\
patients still experiencing other symptoms on day 4;patients given antimalarialspatients given antibioticsNotesCountry: Burkina Faso\
RDT: paracheck (HRP2)\
Setting: peripheral health centres.\
Sampling: convenient selection of health centres to ensure rural/urban representativeness\
Transmission: stable with seasonal transmission\
Dates: 2006; end of dry season and rainy season\
Funding: UNIDEA‐UNICREDIT Foundation***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random list.Allocation concealment (selection bias)Unclear riskNot indicated.Blinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of intervention allocation.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnosis made and treatment prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was generally low (95.4% dry season; 97.3% rainy season) but not differentiated by trial group.\
Performed available case analysis, although reported to have performed intention‐to‐treat analysis.Selective reporting (reporting bias)Low riskReported on all trial outcomes described in the methodology.Other biasLow riskNo other sources of bias identified.[@CD008998-bbs2-0003]MethodsTrial design: cluster randomized pre‐post open‐label trial; data included in this review are from the two months following introduction of RDTs to the intervention arm.ParticipantsNumber of participants randomized: total fever cases 2213 (1073 in RDT arm, 1140 in presumptive treatment arm);\
Number of participants randomized for clinical outcomes was 25% of total fever cases, 553 (268 versus 285 respectively)\
Number of participants analysed for primary outcomes: (a) prescribing of antimalarials analysis 2213 (0% loss); (b) clinical outcomes: 483 (12.7% loss: 19.5% in intervention arm versus 6.3% in presumptive treatment arm)\
Inclusion: Any patient deemed eligible for RDT testing by the healthworker\
Exclusion: NoneInterventionsIntervention: Training in fever case management based on RDTs.\
Control: Standard‐of‐care symptom‐based or empiric treatment of fever.\
The intervention group received training and RDTs; one‐day follow‐up support supervision was conducted two weeks after the initial three‐day training. Data collection commenced after the follow‐up support supervision visit. The control group continued usual symptom‐based care according to existing Uganda Ministry of Health guidelines.\
RDT performed by treating clinician (usually clinical officer or nursing staff).\
No other formal supervision was provided.OutcomesPrimary: patients with fever on day 4\
Secondary:\
patients still experiencing other symptoms on day 4;patients given antimalarials;patients given antibiotics.NotesCountry: Uganda\
RDT: paracheck (HRP2)\
Setting: peripheral health centres\
Sampling: Lack of microscopy services, at least three full‐time clinical staff, estimated patient volume of at least 200 patients per week, willingness of health centre staff to participate in the trial, and location within 20 km of a sentinel health centre established by the Uganda Malaria Surveillance Project.\
Transmission: High; reference slide positivity in all participants with fever: 46%\
Dates: 2008; first half\
Funding: Exxon Mobil Corp. via the Academic Alliance Foundation; and NIH, USA, K23 AI065457‐01***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCoin flip in the presence of health centre leaders.Allocation concealment (selection bias)Unclear riskAllocation of RDTs was decided by coin flip in the presence of study staff and representatives from each matched pair of health centers.Blinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of intervention allocation.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnosis made and treatment prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was low (0.0% for prescribing of antimalarials; 12.7% for clinical outcomes, differentiated by trial group).\
Performed available case analysis.Selective reporting (reporting bias)Low riskReported on all trial outcomes described in the methodology.Other biasLow riskNo other sources of bias identified.[@CD008998-bbs2-0004]MethodsTrial design: cluster randomized pre‐post open‐label trial; data included in this review are from the two months following introduction of RDTs in the intervention arm.ParticipantsNumber of participants randomized: total fever cases 1550 (602 in RDT arm, 948 in presumptive treatment arm)\
Number of participants randomized for clinical outcomes was 25% of total fever cases, i.e.388 (151 versus 267 respectively)\
Number of participants analysed for primary outcomes: (a) prescribing of antimalarials analysis 1550 (0% loss); (b) clinical outcomes: 328 (15.4% loss: 6.3% in intervention arm versus 21.1% in presumptive treatment arm)\
Inclusion: Any patient deemed eligible for RDT testing by the healthworker\
Exclusion: NoneInterventionsIntervention: Training in fever case management based on RDTs.\
Control: Standard‐of‐care symptom‐based or empiric treatment of fever.\
The intervention group received training and RDTs; one‐day follow‐up support supervision was conducted two weeks after the initial three‐day training. Data collection commenced after the follow‐up support supervision visit. The control group continued usual symptom‐based care according to existing Uganda Ministry of Health guidelines.\
RDT performed by treating clinician (usually clinical officer or nursing staff).\
No other formal supervision was provided.OutcomesPrimary: patients with fever on day 4\
Secondary:\
patients still experiencing other symptoms on day 4patients given antimalarialspatients given antibioticsNotesCountry: Uganda\
RDT: paracheck (HRP2)\
Setting: peripheral health centres\
Sampling: Lack of microscopy services, at least 3 full‐time clinical staff, estimated patient volume of at least 200 patients per week, willingness of health centre staff to participate in the trial, and location within 20 km of a sentinel health centre established by the Uganda Malaria Surveillance Project.\
Transmission: Medium; reference slide positivity in all participants with fever 32%\
Dates: 2008; first half\
Funding: Exxon Mobil Corp. via the Academic Alliance Foundation; and NIH, USA, K23 AI065457‐01***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCoin flip in the presence of health centre leaders.Allocation concealment (selection bias)Unclear riskAllocation of RDTs was decided by coin flip in the presence of study staff and representatives from each matched pair of health centersBlinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of intervention allocationBlinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnosis made and treatment prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was low (0.0% for prescribing of antimalarials; 15.4% for clinical outcomes, differentiated by trial group)\
Performed available case analysis,Selective reporting (reporting bias)Low riskReported on all trial outcomes described in the methodologyOther biasLow riskNo other sources of bias identified[@CD008998-bbs2-0005]MethodsTrial design: cluster randomized pre‐post open‐label trial; data included in this review are from the two months following introduction of RDTs in the intervention arm.ParticipantsNumber of participants randomized: total fever cases 4197 (2288 in RDT arm, 1909 in presumptive treatment arm);\
Number of participants randomized for clinical outcomes was 25% of total fever cases, i.e. 1049 (572 versus 477 respectively)\
Number analysed for primary outcomes: (a) prescribing of antimalarials analysis 4197 (0% loss); (b) clinical outcomes: 959 (8.6% loss: 0.2% in intervention arm versus 17.2% in presumptive treatment arm)\
Inclusion: Any patient deemed eligible for RDT testing by the healthworker\
Exclusion: NoneInterventionsIntervention: Training in fever case management based on RDTs\
Control: Standard‐of‐care symptom‐based or empiric treatment of fever\
The intervention group received training and RDTs; one‐day follow‐up support supervision was conducted two weeks after the initial three‐day training. Data collection commenced after the follow‐up support supervision visit. The control group continued usual symptom‐based care according to existing Uganda Ministry of Health guidelines.\
RDT performed by treating clinician (usually clinical officer or nursing staff).\
No other formal supervision was provided.OutcomesPrimary: patients with fever on day 4\
Secondary:\
patients still experiencing other symptoms on day 4;patients given antimalarialspatients given antibioticsNotesCountry: Uganda\
RDT: paracheck (HRP2)\
Setting: peripheral health centres\
Sampling: Lack of microscopy services, at least three full‐time clinical staff, estimated patient volume of at least 200 patients per week, willingness of health centre staff to participate in the trial, and location within 20 km of a sentinel health centre established by the Uganda Malaria Surveillance Project.\
Transmission: Very high; reference slide positivity in all participants with fever 73%\
Dates: 2008; first half\
Funding: Exxon Mobil Corp. via the Academic Alliance Foundation; and NIH, USA, K23 AI065457‐01***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCoin flip in the presence of health centre leaders.Allocation concealment (selection bias)Unclear riskAllocation of RDTs was decided by coin flip in the presence of study staff and representatives from each matched pair of health centersBlinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of intervention allocation.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnosis made and treatment prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was low (0.0% for prescribing of antimalarials; 8.6% for clinical outcomes, differentiated by trial group).\
Performed available case analysis.Selective reporting (reporting bias)Low riskReported on all trial outcomes described in the methodology.Other biasLow riskNo other sources of bias identified.[@CD008998-bbs2-0006]MethodsCluster RCT; randomized by health facilities\
Stratified random selection of facilities, by transmission settings (high/low) and facility type (hospitals, health centres and dispensaries)\
Took into account a design effect of two in sampling\
Reference slide taken. Results not reported\
Trial lasted four monthsParticipantsInclusion: age ≥ 5 years, irrespective of condition\
Number of participants randomized: Intervention arm: 799\
Number analysed for primary outcome (prescribing of antimalarials): 669 (16.3% loss)InterventionsIntervention: RDTs for fever patients ≥ 5 years\
Control: Presumptive treatment of fever\
Boh groups received training and held guidelines\
RDT performed by health workers\
Health workers complied with guidelines partially: 41% of participants with negative RDT results received antimalarialsOutcomesPrimary outcomes:\
Fever patients prescribed ACTMicroscopy negative patients prescribed ACT\
Secondary outcomes:\
RDT negative patients prescribed ACT; and RDT positive patients prescribed ACTPatients prescribed ACT presumptivelyPatients with known alternative diagnosis receiving ACTNotesCountry: Kenya\
RDT: paracheck\
Setting: all referral levels of facilities, 60 in total, 30 in each arm\
Transmission: Hyperendemic or holoendemic at some sites and low and seasonal at others.\
Dates: June to September 2006\
Funding: USAID***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskSystematic allocation.Allocation concealment (selection bias)Unclear riskAlthough probabilistic sampling was used in selecting the participating health facilities, the participants had foreknowledge of intervention assignments.Blinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of intervention allocation.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnoses and prescriptions.Incomplete outcome data (attrition bias) All outcomesHigh riskPer protocol analysis; loss to follow‐up was high, more at the intervention facilities (20.2%) than at the control facilities (11.2%).Selective reporting (reporting bias)Low riskReported on all pre‐specified outcomes (prescribing of ACT); did not explicitly report on overall antimalarial prescribing, but the summary data were available for inclusion in the review.Other biasLow riskBaseline imbalance minimised by stratifying facilities by level and randomly selecting within each level.\
Summary data were adjusted for baseline imbalance.\
Results could be biased towards the null, because some facilities in the comparison arms had RDT.\
Loss of complete clusters: not reported.[@CD008998-bbs2-0007]MethodsCluster randomized, by health posts. Pairs matched by distance from health centre then randomized.\
Patinets follow‐up and clinical status evaluated 5 to 7 days after initial contact.\
Estimates of measures of effects were adjusted for clustering & baseline imbalance using generalised estimating equations with exchangeable correlation matrix.ParticipantsInclusion: Children (6 months to 5 years); presenting with fever with or without other conditions\
Total enrolled and randomized: 3125 (1017 in the RDT arm and 2108 in the clinical diagnosis arm)\
Number analysed for primary outcomes: (a) prescribing of antimalarials: 3047 (2.5% loss); (b) clinical outcomes: 3125 (0% loss)InterventionsIntervention: RDT‐aided algorithm\
Control: Clinical algorithm\
Both groups received training and held guidelines\
RDT performed by health workers; additional interventions provided to increase adherence with RDT results\
Health workers complied with guidelines most of the time: only 0.4% of participants with negative RDT results received antimalarialsOutcomes1. Children with fever who received AL\
2. Children still experiencing symptoms at follow‐up (day 5 to 7)NotesCountry: Zambia\
RDT: ICT Malaria Pf (ICT Diagnostics)\
Setting: Community health posts, manned by community health workers with six‐week training in basic clinical skills, rural and urban\
Sampling: 42 community health posts\
Transmission: High prevalence (valley) and low prevalence (plateau) areas\
Dates: Between December 2007 and November 2008\
Funding: Not provided***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAuthors report random allocation; numbers were generated by random number generator.Allocation concealment (selection bias)Unclear riskParticipants were aware beforehand of the diagnostic procedures they were assigned to.Blinding of participants and personnel (performance bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnostic procedures applied.Blinding of outcome assessment (detection bias) All outcomesHigh riskBoth the trial participants and personnel were aware of the diagnostic outcomes, and the medications prescribed.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up was low and comparable in both settings (2.5% in patients assessed for prescribing of antimalarials; 3% in patients assessed for clinical outcomes).Selective reporting (reporting bias)Low riskReported on all pre‐specified outcomes.Other biasLow riskRecruitment bias was low‐pairs of aid posts were matched by distance then randomized.\
Baseline imbalance: selected clusters were similar and imbalance adjusted for.\
Loss of whole clusters: no loss reported.

Characteristics of excluded studies \[ordered by study ID\] {#CD008998-sec2-0021}
===========================================================

StudyReason for exclusion[@CD008998-bbs2-0008]Not a RCT but a cross‐sectional survey, without a comparison group.[@CD008998-bbs2-0009]Intervention facilities were selected purposively; there was no random assignment to comparison arms.[@CD008998-bbs2-0010]Not a RCT; and examined the effect of withholding anti‐malaria to RDT‐positive children rather than comparing RDT‐based policy with presumptive treatment.[@CD008998-bbs2-0011]Not a RCT.[@CD008998-bbs2-0012]Not a RCT (weekly cross‐over of intervention).[@CD008998-bbs2-0013]Not a RCT(weekly cross‐over of intervention).[@CD008998-bbs2-0014]Comparison was policy based on microscopy rather than presumptive treatment.

JO wrote the protocol and the first draft of the review during his PhD programme at Liverpool School of Tropical Medicine, with input from PG and JAL. JO was responsible for data entry and analysis. JO and JAL independently screened studies for inclusion, assessed risk of bias from the included trials and extracted data from them. PG provided supervision throughout the review process. SD provided advice on the statistical methods. DS reviewed all sections of the review; in particular the trial outcomes, Summary of findings tables, main results, discussion, and conclusion. HH provided unpublished trial data and contributed to the interpretation, and discussion. All authors contributed to the final interpretation and results.

Internal sources {#CD008998-sec2-0018}
================

Liverpool School of Tropical Medicine, UK.

External sources {#CD008998-sec2-0019}
================

Department for International Development (DfID), UK.

The authors have no known conflicts of interest.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ No serious risk of bias: None of these trials adequately described allocation concealment, however this was not downgraded. ^2^ No serious inconsistency: Statistical heterogeneity was low. However, in one trial health worker compliance with the RDT protocol was very low, with a high prescription of antimalarials in both groups. This trial found no effect (RR 1.01), while in the remaining trials with good compliance there is a trend towards benefit with RDTs. ^3^ Downgraded by one for serious indirectness: The only patients who could feasibly benefit from the use of RDT are patients with a negative RDT whose fever is not due to malaria. The management protocol and advice given to health workers about how to manage these patients in these trials is unclear and the effect of RDT use on antibiotic prescribing was highly varied. These five trials were conducted in rural areas in Burkina Faso, Zambia, and Uganda (three trials). The health staff were community health workers, nurses or clinical officers. ^4^ Downgraded by one for serious imprecision: There is a trend towards benefit with RDTs, however this does not reach statistical significance, even when the trial with poor adherence to the RDT protocol was excluded. ^5^ Downgraded by one for serious inconsistency: The size of the reduction in antimalarial prescription varied according to HW compliance with RDT results. In one trial from Burkina Faso, where HW prescribed high levels of antimalarials to negative RDTs, no difference in antimalarial prescription was seen. In the remaining six trials HW compliance was much higher, and prescriptions lower ^6^ No serious indirectness; These trials were mainly conducted in rural settings in Africa, with a range of malaria endemicity. ^7^ No serious imprecision:. Statistically significant differences were seen in all six trials with moderate or high heathworker adherence ^8^ Downgraded by two for very serious inconsistency: There is a large range of effects both increasing and decreasing antibiotic use across trials. ^9^ Downgraded by one for serious indirectness: The only patients who could feasibly benefit from the use of RDT are patients with a negative RDT whose fever is not due to malaria. The management protocol and advice given to health workers about how to manage these patients in these trials is unclear ^10^ No serious risk of bias: This trial was individually randomized and at unclear risk of selection bias. ^11^ Downgraded by one for serious indirectness: Only one trial conducted microscopy on all participants. This trial was conducted in Ghana in an area of unclear endemicity. The number of missed diagnoses is likely to vary with malaria endemicity. In the three trials from Uganda which only conducted microscopy on participants in the RDT arm: the negative predictive value was 0.96 in the very high endemic setting, 0.97 in the high endemic setting, and 0.93 in the medium endemic setting. ^12^ Downgraded by one for serious imprecision: The 95% CI is wide including what may be clinically important increase in missed cases.

[^3]: ^1^ Skarbinski 2009 KEN: 2004 participants were randomized but outcomes were collected through baseline and post intervention surveys. 669 participants were evaluated in teh post‐intervention survey.

[^4]: ^1^ The endemicity classification is the Cochrane Review authors\' judgement based on the proportion of RDTs testing positive: Very high = \> 60%; High = 40% to 59%; Moderate = 6% to 39%. ^2^ The health worker adherence classification is the Cochrane Review authors\' judgement and is based on the difference between the proportion of RDTs testing positive and the proportion of patients being prescribed antimalarials in the RDT arm: High = difference \< 10%; Moderate = difference 11% to 20%; Low = difference 21% to 30%; Very low = difference \> 30%. ^3^ For [@CD008998-bbs2-0006], the proportion of RDTs testing positive was unavailable.

[^5]: ^1^ This data has been taken from the trial data of [@CD008998-bbs2-0005], [@CD008998-bbs2-0003], & [@CD008998-bbs2-0004], and converted into a percentage. ^2^ TP = True positive = RDT positive and microscopy positive ^3^ FP = False positive = RDT positive and microscopy negative ^4^ TN = True negative = RDT negative and microscopy negative ^5^ FN = False negative = RDT negative and microscopy positive ^6^ Sensitivity = The proportion of people with fever due to malaria correctly identified with a positive RDT result = TP/(TP+FN) ^7^ Specificity = The proportion of people with fever due to non‐malaria illness correctly identified with a negative RDT result = TN/(TN+FP) ^8^ NPV = Negative predictive value = The proportion of people with a negative RDT result who have a non‐malaria cause of their fever = TN/(TN+FN) ^9^ PPV = Positive predictive value = The proportion of people with a positive RDT result who have malaria as a cause of their fever = TP/(TP+FP)
